Volume 95 Issue 36 | p. 13 | Concentrates
Issue Date: September 11, 2017

Merck buys cancer firm Rigontec

Department: Business
Keywords: Oncology, immuno-oncology, RNA

Bolstering its immuno-oncology pipeline, Merck & Co. will pay roughly $135 million to acquire the German biotech firm Rigontec. The deal adds RNA-based therapies targeting the retinoic acid-inducible gene I (RIG-I) pathway, a component of the innate immune system, and includes a RIG-I agonist in Phase I studies as a cancer treatment. Investors in Rigontec, which was spun off of the University of Bonn in 2014, could receive another $415 million if certain milestones are . . .

To view the rest of this content, please log in with your ACS ID.



 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society